The short version
10 companies supply this market — deep enough that no single failure threatens the supply.
Market view
fosaprepitant · Injection, Powder, Lyophilized, For Solution
13 marketed package NDCs · 10 active manufacturers
Most dispensed: DIMEGLUMINE 150 mg/5mL · Injection, Powder, Lyophilized, For Solution · #1 vial, single-dose/carton / 5 ml in 1 vial, single-dose · DIMEGLUMINE 150 mg/5mL · Injection, Powder, Lyophilized, For Solution · #1 vial/carton / 1 ml in 1 vial · DIMEGLUMINE 150 mg · Injection, Powder, Lyophilized, For Solution · #1 injection, powder, lyophilized, for solution/carton · DIMEGLUMINE 150 mg/5mL · Injection, Powder, Lyophilized, For Solution · #1 vial, single-dose/carton / 10 ml in 1 vial, single-dose
Price range and competition
RSS: changes for this drugpriced separately — they are not the same market
Generic products only. Every company selling this drug reports its own price. The line follows the middle of the pack; the shaded band holds the middle half of companies — the wider it is, the more they disagree.
Latest · Feb 2025 — typical price $38.51 · middle half $38.51–$38.51 · full range $38.51–$38.51 · 6 products · 8 companies
ⓘ How this was built
Data sources
- CMS NADAC weekly survey + monthly archives back to 2013 (data.medicaid.gov)
- CMS Federal Upper Limit files (weighted AMP)
- FDA NDC Directory (openFDA) — maker roster
Method
Each month's band spans the NADAC unit prices of every NDC of this drug (min, quartiles, median, max), split into brand and generic cohorts by FDA marketing category. Maker counts come from distinct labelers with the NDC actively listed.
Pipeline and calculations built by Claude (Fable 5) from the public datasets above. Educational only — verify against primary sources before acting.
What changed in the last 90 days
Every detected change for fosaprepitant, newest first — price moves, shortages, recalls, and manufacturers entering or leaving. Detected by comparing each day’s federal data against the day before.
Same drug class
Other molecules FDA puts in Substance P/Neurokinin-1 Receptor Antagonist, with whether each is in shortage right now. Same class is not the same drug — substitution is a clinical decision, and this is a supply picture, not a recommendation.
Common questions
- Is Fosaprepitant in shortage right now?
- No. FDA does not currently list Fosaprepitant in shortage. This page is rebuilt every morning from FDA's shortage database, so a new posting appears here the day it is published.
- Who makes Fosaprepitant?
- 10 companies have marketed Fosaprepitant in the last 30 days, according to the FDA NDC Directory. Every manufacturer and package is listed on this page.
Shortage reports for this molecule
- Planned discontinuation — Fosaprepitant Dimeglumine, Injection, 150 mg/5 mL (NDC 63323-972-10)Apr 8, 2026
All marketed products
Expand a strength to see its dosage forms, then package sizes, then each manufacturer and NDC. Click an NDC for its full detail page.